[Danazol in the therapy of dysfunctional uterine hemorrhage in women of fertility age].
The effectiveness of Danazol in a dose of 200 mg/day for 3 consecutive months has been assessed in 30 women complaining of dysfunctional uterine haemorrhages. The patients were selected by excluding any associated genital pathology (myomas, ovarian neoformations, endometrial cancer, etc.) and any clotting pathology. Danazol proved effective in all cases treated. Side-effects were inconsequential save for 2 women who had to suspend treatment following increase in transaminases in one case and defluvium capitis in the other. The treatment remained effective for at least 2 months after termination. In 26% of the women, the haemorrhagic pathology reappeared within 6 months but, apart from one case, repetition of the cycle using the same modalities as before, mastered and normalised the menstrual picture.
M
M
Bardi
D000328:Adult; D003613:Danazol / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008598:Menstruation / Q000187:drug effects; D008875:Middle Aged; D011245:Pregnadienes / Q000627:therapeutic use*; D014592:Uterine Hemorrhage / Q000188:drug therapy*
D011245:Pregnadienes; D003613:Danazol
II Danazol nella terapia delle emorragie uterine disfunzionali nella donna in età fertile.